Daiichi Sankyo poised to add another ADC blockbuster with datopotamab deruxtecan for non-squamous…
GlobalData estimates the drug to earn $3.12 billion by 2029
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
NSCLC
AstraZeneca’s Tagrisso to lead lung cancer small molecule market with over $7 bn sales by 2029:…
GlobalData reveals that a total of 39 small molecules have been commercialised for the treatment of lung cancer, with a total of…
European Commission approves Roche’s Gavreto to treat adults with RET fusion-positive advanced…
Gavreto is the first and only precision medicine approved in the EU for the first-line treatment of people with RET…
US FDA nod for Roche’s VENTANA ALK (D5F3) CDx assay as companion diagnostic for NSCLC…
The VENTANA ALK (D5F3) CDx Assay is now FDA approved as a companion diagnostic in four targeted treatments
Pfizer gets full US FDA nod for LORBRENA as first-line treatment for ALK-Positive metastatic NSCLC
Approval is based on CROWN trial, which showed a 72 per cent reduction in risk of progression or death for treatment with LORBRENA…